

Date: September 5, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scheme of amalgamation of Casper Pharma Private Limited (a wholly owned subsidiary of Suven Pharmaceuticals Limited) into and with Suven Pharmaceuticals Limited under Sections 230 and 232 of the Companies Act, 2013 and other applicable rules and/or regulations.

Dear Sir/Madam,

This is with reference to, and in furtherance of: (a) our letter dated February 29, 2024, regarding the decision of the Board of Directors of Suven Pharmaceuticals Limited approving the Scheme of Amalgamation of Casper Pharma Private Limited (a wholly owned subsidiary of Suven Pharmaceuticals Limited) (“**Transferor Company**”) into and with Suven Pharmaceuticals Limited (“**Transferee Company**”) under Sections 230 and 232 of the Companies Act, 2013 and other applicable rules and/or regulations, subject to receipt of applicable regulatory and other approvals (the “**Scheme of Amalgamation**”); and (b) our letter dated June 15, 2024, regarding the subsequent receipt of the order from the Hon’ble NCLT dispensing with the meetings of equity shareholders, secured creditors and unsecured creditors of both the Transferor Company and the Transferee Company, and directing service of notices to regulatory authorities.

In the above context, as an update, we are pleased to inform that now the Hon’ble NCLT, Mumbai Bench by way of its order (as uploaded on the official website of the NCLT (<https://nclt.gov.in/>) on September 4, 2024) has listed the matter on October 4, 2024 for hearing and final disposal of the application on the abovementioned Scheme of Amalgamation.

We request you to take this disclosure on your records.

Thanking you.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236